Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IBC 2024 | AI-REAL: improving diagnosis and treatment in EBV-associated Burkitt lymphoma

Anna Schuh • 25 Mar 2024
IBC 2024
Burkitt Lymphoma Lymphoma Antibodies Rituximab Vaccines

In this video, Anna Schuh, MD, PhD, FRCP, FRCPath, University of Oxford, Oxford, UK, gives an overview of the AI-REAL program, which is an ongoing study that aims to improve diagnosis and treatment in children with EBV-associated Burkitt lymphoma in Sub-Saharan Africa. Prof. Schuh also highlights ongoing research into a vaccine against EBV, which could play a crucial role in preventing post-treatment relapse in these children. This session was filmed at IBC 2024, held in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Anna Schuh

3:04
Facilitating diagnosis of Burkitt lymphoma in children in Uganda and Tanzania
Anna Schuh • 7 Oct 2023
1:48
The OxPLoreD study: T-cell type abundance and gene expression in early lymphoproliferative disorders
Anna Schuh • 7 Oct 2023
1:52
Genomic stratification of patients with CLL
Anna Schuh • 7 Oct 2023
1:56
STELLAR: genomic sequencing of ctDNA reveals additional driver mutations in Richter's transformation
Anna Schuh • 7 Oct 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals